| January 2 |
New Year's Resolution - Get Healthy |
| January 4 |
2006 - The Year in Drugs |
| January 4 |
Generic Drug Approvals for December 2006 |
| January 5 |
FDA Approves Slentrol - the First Drug for Obese Dogs |
| January 9 |
FDA Approves MedImmune's Refrigerated Formulation of FluMist |
| January 9 |
Purdue will launch first medication-error investigation program in U.S. |
| January 10 |
Use of Corticosteroid Inhalers for the Treatment of Asthma and COPD to Increase |
| January 10 |
Genentech Announces Full Year and Fourth Quarter 2006 Results |
| January 11 |
The National Association of Boards of Pharmacy Warns About the Continued Dangers of Counterfeit Prescription Drugs |
| January 11 |
Prescription Drugs - An Overview of Approaches to Negotiate Drug Prices Used by Other Countries and U.S. Private Payers and Federal Programs |
| January 11 |
GenVec Receives Clearance From FDA for EUS Administration of
TNFerade |
| January 11 |
Elaprase for the Treatment of Hunter Syndrome Approved by the
European Commission |
| January 11 |
Wyeth and Solvay Enter Into an Additional Neuroscience
Collaboration |
| January 11 |
Bristol-Myers Squibb and AstraZeneca Announce Worldwide
Collaboration to Develop and Commercialize Diabetes Compounds |
| January 11 |
Astellas Terminates Agreement on Acute Heart Failure Agent
Carperitide |
| January 11 |
The European Commission Approves First and Only Enzyme Replacement
Therapy for Hunter Syndrome |
| January 11 |
Bayer and Onyx Announce Pivotal Nexavar Kidney Cancer Study
Published in New England Journal of Medicine |
| January 11 |
FDA Clarifies Path to Review Completion for MDS Bioanalytical
Clients |
| January 11 |
Biopure Provides Further Comment on U.K. Regulatory Body Letter
Regarding Marketing Application for Hemopure |
| January 11 |
Valeant Pharmaceuticals & Metabasis Therapeutics Close
Licensing Deal with Schering-Plough Corporation |
| January 11 |
FDA Notifies Pharmaceutical Companies to Confirm or Repeat Analytic
Studies Used in the Approval of a Number of Drug Products |
| January 11 |
U.S. Congress Threatens Canada's Prescription Drug Supply |
| January 11 |
Entelos Acquires Option to Phase I Compound from Johnson &
Johnson Pharmaceutical Research & Development, L.L.C. |
| January 11 |
Organon to Submit Antidepressant Mirtazapine for Approval in Japan
Significantly Earlier Than Expected |
| January 11 |
Lilly Announces Strategic Changes to its Global Manufacturing
Operations |
| January 11 |
AstraZeneca and Bristol-Myers Squibb Announce Worldwide
Collaboration To Develop And Commercialise Diabetes Compounds |
| January 11 |
PhRMA Statement on PDUFA Reauthorization Proposals |
| January 11 |
PRESCRIPTION DRUGS- An Overview of Approaches to Negotiate Drug
Prices Used by Other Countries and U.S. Private Payers and Federal
Programs |
| January 11 |
FDA Proposes New Measures to Strengthen Drug Safety Under PDUFA
Reauthorized User Fee Program |
| January 12 |
Astellas Pharma US, Inc. Announces Availability of Mycamine 100mg
Vial |
| January 12 |
SCAI Issues Clinical Alert on Drug-Eluting Stents and Late
Thrombosis |
| January 12 |
Bioinvent Enters Collaboration with Genentech to Develop and
Commercialize Bioinvent's Proprietary Antibody for the Potential
Treatment of Cardiovascular Diseases |
| January 12 |
Forest Laboratories Announces Completion of Acquisition of Cerexa,
Inc. |
| January 12 |
Cipralex Approved for the Treatment of Obsessive Compulsive
Disorder |
| January 12 |
UCB and Schwarz Pharma Start Preparations for Domination and Profit
Transfer Agreement |
| January 12 |
UCB and Schwarz Pharma Reach Principle Decision on Group
Integration by Domination and Profit Transfer Agreement |
| January 12 |
Euroscreen Products SA Acquired by PerkinElmer Inc. |
| January 12 |
First Roche GS-FLX Genome Sequencing System Installed at VBI |
| January 12 |
ReNeuron to Commence Phase I Study of ReN001, Stem Cell Therapy |
| January 12 |
Sanofi-Aventis Intends to Contest in Court the Decision to Classify
Acomplia Among Non-reimbursable Drugs in Germany |
| January 12 |
Rep. Pelosi: Requiring Medicare Prescription Drug Negotiation Is a
Resounding Victory for America’s Seniors |
| January 13 |
Resistance to the Use of Prescription Drugs to Treat Addiction Disorders is a Significant Barrier to Market Growth |
| January 15 |
Glass Lewis and PROXY Governance Recommend ICOS Shareholders Vote
for Lilly's $34 Per Share Cash Merger |
| January 15 |
PhRMA Statement on HR 4 |
| January 15 |
Genzyme Announces Publication of Study Showing Impact of Cerezyme
on Bone Health for Patients With Type 1 Gaucher Disease |
| January 15 |
Novo Nordisk Focuses Research and Development on Therapeutic
Proteins - Discontinues R&D Within Small Molecules |
| January 15 |
Tanox, Inc. Stockholders Approve Merger With Genentech, Inc. |
| January 16 |
Study finds 90 Percent of Actiq 'Lollipop' Prescriptions are Off-label |
| January 16 |
Enrollment Completed in Pivotal Phase III Study Comparing Prasugrel
to Clopidogrel in Patients With Acute Coronary Syndrome |
| January 16 |
Merck Serono Completes Patient Enrollment in CLARITY Phase III
Pivotal Clinical Trial of Oral Cladribine |
| January 16 |
UK Court of Appeal Releases Decision on Angiotech Patent |
| January 16 |
Boston Scientific Comments on U.K. Court Decision on Angiotech
Patent |
| January 16 |
Forest Laboratories, Inc. Reports Q3'07 Diluted Earnings Per Share
of $0.78 |
| January 16 |
Beijing Med-Pharm Corporation Wins Bidding for Shares of Chinese
Drug Distributor Shanghai Rongheng |
| January 16 |
Wellbutrin XR Receives First European Approval |
| January 16 |
European Union Meeting Performance Goals for New Drug Review, But
Lags Behind U.S. in New Drug Availability, According to Tufts
Center for the Study of Drug Development |
| January 16 |
Merck Serono Announces Positive Results From Phase III Diet Study
of Phenoptin for Phenylketonuria |
| January 16 |
Genizon BioSciences Announces a License and Collaboration Agreement
with Pfizer in Three Major Diseases |
| January 16 |
Neupro Now Approved in Europe for All Stages of Parkinson's Disease |
| January 16 |
Inex Pharmaceuticals Announces Appeal Date for Spin-out of Tekmira
Pharmaceuticals |
| January 16 |
Crucell Announces Star Research License Agreement with Novo Nordisk
A/S |
| January 16 |
MediciNova Announces Results From a Phase II/III Interstitial
Cystitis Trial With MN-001 |
| January 16 |
More European Patients with Epilepsy to Benefit from Keppra |
| January 16 |
Nycomed Officially Launched as Combined Group |
| January 17 |
Barr Launches Generic Metaglip Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg |
| January 17 |
Eisai Research Institute Opens New 150,000 Square Foot Facility in
Andover to Enhance Basic Discovery Research Capabilities |
| January 17 |
New Transfusion Therapies Company to Be Named 'Fenwal' |
| January 17 |
Archemix and Merck KGaA to Collaborate on Aptamer-Based Cancer
Therapeutics |
| January 17 |
GlaxoSmithKline Awarded $63 Million HHS Contract for Pandemic
Vaccine Research and Development |
| January 17 |
Cipher's Response to Approvable Letter for CIP-ISOTRETINOIN
Accepted for Review by FDA |
| January 17 |
Evidence Lacking to Support Many Off-Label Uses of Atypical
Antipsychotics |
| January 17 |
Bureau of Competition Issues FY 2006 Summary of Pharmaceutical
Company Settlement Agreements |
| January 17 |
Additional Generic Versions of Blockbuster Cholesterol-Lowering
Drug Zocor Creates Generic Competition and Significantly Reduces
Costs |
| January 17 |
Vioxx Trial Update:Statement on Vioxx Product Liability Trial in
New Jersey |
| January 18 |
Anesiva Announces Clinical Data From Phase 1 Trial of 1207 |
| January 18 |
GlaxoSmithKline Initiates Head-to-Head Study of Cervical Cancer
Vaccines |
| January 18 |
IMPAX Files Amendment to Vadova NDA |
| January 18 |
Preliminary Results: Merck KGaA Posts Record 2006 Profit After Tax
of EUR 1 Billion |
| January 18 |
Adherex Buys Out Eniluracil Development Options From
GlaxoSmithKline |
| January 18 |
FDA Approves 18-Month Shelf Life for Taxus Stent System |
| January 18 |
Novartis Strategic Healthcare Portfolio Drives Sustained Strong
Performance with Record Full-year Results in 2006 |
| January 18 |
Exforge Approved in Europe as Powerful New Blood Pressure Therapy
Combining Two Leading Medications in a Single Pill |
| January 18 |
NicOx Receives Euro 5 Million Milestone Payment From Merck &
Co. for Antihypertensive Collaboration |
| January 18 |
Pfizer's Sutent Is Granted Full Marketing Authorization for
First-Line Use in Advanced Kidney Cancer in the European Union |
| January 18 |
Submission of an Application for an additionalIndication of Actos
in Japan; Concomitant Therapy with Biguanides for Type 2 Diabetes |
| January 18 |
Endo Pharmaceuticals Receives Subpoena From U.S. Department of
Health and Human Services |
| January 18 |
Cipralex Approved in Europe for the Treatment of Obsessive
Compulsive Disorder |
| January 18 |
Hospira Acquisition of Mayne Pharma Clears U.S. Antitrust Review |
| January 18 |
FTC Challenges Hospira/Mayne Pharma Deal |
| January 19 |
Vioxx Plaintiffs Failed to Prove Their Cases |
| January 19 |
Abbott To Sell Its Core Laboratory Diagnostics Business, Including
Point Of Care, To GE For $8.13 Billion |
| January 19 |
Lilly ICOS LLC Reports Results for 2006 |
| January 19 |
S-1 Oral Anticancer Agent Improves Patients' Survival In Adjuvant
Gastric Cancer Trial Versus Surgery Alone |
| January 19 |
Statin Plus Cancer Drug Deliver Combo Punch to Brain Cancer Cells |
| January 19 |
Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor
for Capsaicin-induced Pain |
| January 19 |
Mitsubishi Chemical Holdings Corporation: Notice Concerning Certain
Media Reports |
| January 19 |
Platinum Equity Completes Acquisition of Healthcare Marketing
Services Unit from Cardinal Health |
| January 19 |
Health Canada Approves Cangene's Anti-Hepatitis B Product |
| January 22 |
Pfizer Achieves Key 2006 Financial Targets |
| January 22 |
PharmAthene and Healthcare Acquisition Corp. Announce Definitive
Merger Agreement |
| January 22 |
FDA Commissioner Announces Important Personnel Changes |
| January 22 |
FDA Sends Daiichi Sankyo Warning Letter |
| January 22 |
Novartis and Mochida Pharmaceutical to Co-promote Diovan in Japan |
| January 22 |
Evotec Wins Key Contracts With Solvay Pharmaceuticals:
Fragment-Based Drug Discovery and a Third Extension of the Library
Synthesis and Medicinal Chemistry Collaboration |
| January 22 |
Eisai Announces Inovelon Receives Marketing Authorization Approval
from European Commission |
| January 22 |
Paramount Acquisition Corp. Announces Termination of Proposed
Business Combination With BioValve Technologies, Inc. |
| January 22 |
Plaintiff Drops Vioxx Suit Against Merck Five Weeks Before First
Trial in Philadelphia State Court |
| January 22 |
AstraZeneca Makes $100M Research Investment In Boston |
| January 22 |
Pfizer Announces Priorities to Drive Improved Performance, Position
Company for Future Success and Enhance Total Shareholder Return |
| January 22 |
Acumen Pharmaceuticals Inc. Announces Milestone Achievement in
Collaboration With Merck & Co., Inc. |
| January 23 |
Daily Use of Antidepressants Associated with Increased Risk of
Fracture in Older Adults |
| January 23 |
Johnson & Johnson Reports Fourth-Quarter and Full-Year 2006
Results |
| January 23 |
Otsuka Pharmaceutical Co., Ltd. Announces Establishment of New
Organization |
| January 23 |
Astellas Receives an Action Letter from FDA for NDA of FK506 MR in
the U.S. |
| January 23 |
Shire Licenses the North American Rights for SPD754 (apricitabine)
to Avexa Ltd |
| January 23 |
Stiefel Laboratories Receives FDA Approval of Olux-E (Clobetasol
Propionate) Foam, 0.05% for Treatment of Psoriasis and Eczema |
| January 23 |
Cell Therapeutics Reaches Agreement With U.S. Attorney's Office |
| January 23 |
Neurocrine Announces Plans to Resubmit NDA for Indiplon Capsules in
Q2 2007 |
| January 23 |
Coley Pharmaceutical Group Suspends Independent Development of
Actilon; Concentrates Efforts on Preclinical TLR Therapeutics
Product Candidates |
| January 23 |
Wyeth Receives Approvable Letter From FDA for Pristiq
(Desvenlafaxine Succinate) for the Treatment of Major Depressive
Disorder |
| January 24 |
FDA Statement on Effectiveness of Newer Birth Control Pills |
| January 24 |
Abbott Reports Strong Fourth-Quarter Results and Record Operating
Cash Flow in 2006 |
| January 24 |
Kirin and Astellas Enter Into Licensing Agreement on
Immunosuppressive Fully Human Monoclonal Antibody |
| January 24 |
Renovis Restructures to Focus on Advancing Its Neurological and
Inflammatory Disease Programs Into Clinical Trials |
| January 24 |
Merck Serono Has Initiated the ONWARD Study to Evaluate Oral
Cladribine as Add-on Treatment for Multiple Sclerosis |
| January 24 |
Lucentis Receives Approval in the European Union |
| January 24 |
The Medicines Company Determines Not to Proceed with Proposed
Offering |
| January 24 |
First Actemra Multinational Phase III Trial Demonstrates
Significant Improvement in Signs and Symptoms of Rheumatoid
Arthritis |
| January 24 |
MichBio Will Assist Displaced Pfizer Employees |
| January 24 |
Innogenetics Files to Reinstate Jury's Willfulness Verdict in
Successful Patent Infringement Case Against Abbott Laboratories |
| January 24 |
Newer Class of Antidepressants Similar in Effectiveness, But Side
Effects Differ |
| January 25 |
Cardiovascular Drugs, Four Other Therapeutic Classes of Drugs Dominate the Market |
| January 25 |
WHO Revives Efforts to Eliminate Forgotten Disease |
| January 25 |
Bristol-Myers Squibb Company Reports Financial Results for the
Fourth Quarter and Twelve Months of 2006 and Announces EPS Guidance
for 2007 |
| January 25 |
Baxter's Fourth Quarter Financial Results Exceed Expectations |
| January 25 |
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular
Non-Hodgkin's Lymphoma |
| January 25 |
Akzo Nobel Reconfirms Listing of Organon BioSciences |
| January 25 |
Cardinal Health to Sell Pharmaceutical Technologies and Services
Segment to The Blackstone Group for $3.3 Billion |
| January 25 |
Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the
Treatment of Overactive Bladder |
| January 25 |
Bayer Discontinues Trasylol Clinical Trial Program in Non-CABG
Indications |
| January 25 |
Januvia, First in New Class of Oral Treatments Known as DPP-4
Inhibitors, Recommended for Approval for the Treatment of Type 2
Diabetes in the European Union |
| January 25 |
Committee for Medicinal Products for Human Use Summary of Positive
Opinion for Xelevia |
| January 25 |
Committee for Medicinal Products for Human Use Summary of Positive
Opinion for Januvia |
| January 25 |
Committee for Medicinal Products for Human Use Post-authorisation
Summary of Positive Opinion for Xyrem |
| January 25 |
Committee for Medicinal Products for Human Use Post-authorisation
Summary of Positive Opinion for Prevenar |
| January 25 |
ICOS Shareholders Vote to Approve Merger With Eli Lilly |
| January 25 |
FDA Advisory Committee Recommends Licensure of New Pediatric
Combination Vaccine |
| January 26 |
Pfizer Gains Favorable Ruling From Canadian Court on Lipitor Basic
Patent, Will Appeal Ruling on Calcium Salt Patent |
| January 26 |
Copegus Approved in Japan as Combination Therapy with Pegasys for
Patients with Chronic Hepatitis C |
| January 26 |
Astellas and Pfizer Reached Settlement on Declaratory Judgment
Action Relating to Lipitor Agreement |
| January 26 |
BioVeris Completes Additional Vaccine License |
| January 26 |
Antiviral Agent Copegus Tablet 200 mg Received Approval as a
Combination Therapy with Chronic Hepatitis C Treatment Drug Pegasys |
| January 26 |
European Medicines Agency Adopts Positive Opinion Recommending
Approval of Xyrem for the Treatment of Narcolepsy with Cataplexy in
Adult Patients |
| January 26 |
Amgen's Fourth Quarter 2006 Revenue Increased 17% to $3.8 Billion;
Full Year 2006 Revenue Increased 15% to $14.3 Billion |
| January 26 |
Bayer Schering Pharma AG Announces Oral Formulation of Fludara
Approved in Japan |
| January 26 |
Illumina Announces the Completion of Its Acquisition of Solexa |
| January 29 |
USP Publishes Standards for Medications for Neglected Diseases |
| January 29 |
iCardiac Technologies Enters Into Cardiac Safety Alliance With
Pfizer |
| January 29 |
Kyowa Hakko Nine-Month Operating Income up 17.5% |
| January 29 |
Unigene Enters Supply Agreement to Manufacture Osteoporosis Peptide |
| January 29 |
Tarceva : European Approval for Pancreatic Cancer Treatment |
| January 29 |
OSI Pharmaceuticals Announces European Regulatory Approval of
Tarceva for Treatment of Patients with Pancreatic Cancer |
| January 29 |
GlaxoSmithKline Files Its New Pre-Pandemic Influenza Vaccine in
Europe |
| January 29 |
Genelabs Technologies Announces Sale of Equity in Taiwan-Based
Biotechnology Company |
| January 29 |
Shionogi: Consolidated Financial Results for the Third Quarter of
Fiscal Year 2006 |
| January 29 |
Genentech and Tanox Receive 'Second Request' from the Federal Trade
Commission |
| January 29 |
Schering-Plough Reports Financial Results for 2006 Fourth Quarter,
Full Year |
| January 29 |
FDA MedWatch: Aranesp (darbepoetin alfa) Study Showing the Drug
Ineffective in Reducing RBC Transfusions or Fatigue in Cancer
Patients with Anemia and a Higher Mortality Rate Observed in the
Aranesp Treatment Group |
| January 29 |
Pharmion Corporation Announces FDA Approval of Vidaza NDA
Supplement for IV Administration |
| January 29 |
Wyeth Pharmaceuticals Listed as the Best 10 Pipeline for the Third
Consecutive Year by R&D Directions Magazine |
| January 29 |
United States Joins Suit Against Pharmaceutical Manufacturer
Boehringer Ingelheim Roxane Inc. |
| January 30 |
Innovative Long-Acting Contraceptive Product Mirena Approved in
Japan |
| January 30 |
Merck Announces 2006 Financial Results that Demonstrate Solid
Revenue Growth |
| January 30 |
Merck Serono Launches Easypod, First Electronic Growth Hormone
Injection Device |
| January 30 |
Proton Pump Inhibitor Pariet Tablets 10mg Receives Approval in
Japan for Helicobacter Pylori Eradication |
| January 30 |
Lilly Announces Completion of ICOS Corporation Acquisition |
| January 30 |
Wyeth Reports Earnings Results for the 2006 Fourth Quarter and Full
Year |
| January 30 |
P&G Delivers 17% EPS Growth - Raises Fiscal Year Outlook |
| January 30 |
Leading Healthcare Companies Join in Major Research and Development
Effort to Prevent Heart Attack and Stroke |
| January 30 |
New Physician Survey Finds FDA Too Slow in Approving New Drugs and
Devices |
| January 30 |
A New Laser Weapon Against Counterfeit Drugs |
| January 30 |
LifeSpan BioSciences Enters into Agreement with Roche for Expanded
DrugTarget Localization Database |
| January 30 |
FDA Approves NovoLog Category Change for Use in Pregnant Women with
Type 1 Diabetes |
| January 30 |
Pfizer Canada to Streamline Pharmaceutical Operations to Improve
Performance and to Better Meet Emerging Customer and Business Needs |
| January 31 |
NeuroDerm's Transdermal L-DOPA Parkinson's Patch Completes First Clinical Trial |
| January 31 |
The Practice of Authorized Generics During the 180-Day Exclusivity
Period May Be Nearing its End With the Introduction of S. 438 -
'The Fair Prescription Drug Competition Act of 2007' |
| January 31 |
AstraZeneca and Palatin Technologies Announce Worldwide
Collaboration to Discover, Develop and Commercialise Obesity
Compounds |
| January 31 |
Lilly Announces 2006 Adjusted EPS of $3.18 Excluding Charges and
Reported EPS of $2.45 |
| January 31 |
FDA Reinforces Commitment to Drug Safety |
| January 31 |
Avanir Receives FDA Approvable Letter for New Formulation of
Currently Marketed Antipsychotic Drug FazaClo |
| January 31 |
Novo Nordisk: Financial statement for 2006 |
| January 31 |
CSL to File Pandemic Vaccine Dossier with the Therapeutic Goods
Administration |
| January 31 |
Daiichi Sankyo: Consolidated Financial Results for the First Nine
Months of Fiscal 2006 |
| January 31 |
YM BioSciences Announces Termination of the Tesmilifene Phase III
Pivotal Trial in Advanced Breast Cancer |
| January 31 |
Mylan Laboratories Announces Strategic Global Reorganization to
Maximize Growth Opportunities and Leverage Efficiencies Provided by
New Global Platform |
| January 31 |
Polydex Pharmaceuticals reports Phase III trial of Ushercell for
HIV Prevention Halted |
